Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

FDA clearance enables AAVantgarde's AAVB-039 to enter Phase 1/2 CELESTE trial in Stargardt disease, restoring robust ABCA4 expression.
May 12, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting

AAVantgarde presents positive Phase 1/2 safety data for Usher 1B and preclinical safety data for Stargardt at ARVO 2025, supporting future trials.
April 28, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer

AAVantgarde Bio appoints Rasmus Holm-Jorgensen as CFO to support growth and advance AAV gene therapies for inherited retinal diseases.